Results 1 to 4 of about 9 (4)

A novel and safe SmartCap<sup>®</sup> SC101 to develop the COVID-19 mRNA vaccine STP2104 inducing potent immune responses in humans. [PDF]

open access: goldFront Immunol
We have developed a 5′-capping library screening (CLS) method using over 30 different novel cap analogues. The optimal 5′-cap for the coronavirus disease 2019 (COVID-19) mRNA vaccine STP2104 was selected and applied. This is the first report to describe the proven safety of the novel cap analogue, SmartCap® SC101, in humans and emphasize the importance
Kim R   +23 more
europepmc   +7 more sources

Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method. [PDF]

open access: goldFront Immunol
Messenger RNA (mRNA) vaccines represent a critical avenue for coronavirus disease 2019 (COVID-19) prevention. We developed a COVID-19 mRNA vaccine encoding a codon-optimized full-length ancestral spike (S) protein with a signal peptide, which employs our novel patented co-transcriptional 5′-capping reagent, SmartCap®. From the screening capping library
Choi K   +36 more
europepmc   +5 more sources

Table 1_Discovery and development of a safe and efficient COVID-19 mRNA vaccine, STP2104, using a novel capping library screening method.docx

open access: green
Kanghyun Choi (21507536)   +36 more
openalex   +1 more source
Home - About - Disclaimer - Privacy